Table 4.
Follow-up of 13 Chinese GS pedigrees
| Pedigree | Patient | Treatment | K+ (mmol/L) | Mg2+ (mmol/L) | Symptom | |||
|---|---|---|---|---|---|---|---|---|
| Oral KCl (mmol/d) | PAMA | Sp (mg/d) | ||||||
| K (mmol/day) | Mg (mg/day) | |||||||
| A | II 1(M) | 40.27 | 8.35 | 106.2 | – | 2.90–3.00 | 0.70–0.90 | A |
| B | II 1(M) | 80.54 | 5.57 | 70.8 | 120 | 2.60–2.80 | 0.60–0.70 | A |
| C | II 1(M) | 80.54 | 5.57 | 70.8 | – | 3.00–3.10 | 0.56–0.64 | A |
| II 2(M) | 13.42–40.27 | – | – | – | 3.10–3.20 | 0.59–0.62 | A | |
| D | II 1(F) | 40.27 | 11.14 | 141.6 | 40 | 3.40–3.50 | 0.60–0.70 | A |
| E | II 1(M) | 40.27 | 8.35 | 106.2 | – | 2.90–3.30 | 0.70–0.80 | A |
| F | II 1(M) | 40.27 | 8.35 | 106.2 | – | 3.00–3.30 | 0.60–0.70 | A |
| G | II 1(M) | 93.10 | 8.35 | 106.2 | – | 3.20–3.50 | 0.70–0.90 | A |
| II 3(F) | – | – | – | – | 3.40–3.50 | 0.80–0.90 | A | |
| H | II 3(M) | ※ | 22.28 | 283.2 | 60 | 3.00–3.50 | 0.40–0.50 | Paralysis, tetany, cramps |
| II 2(F) | 13.42–40.27 | 11.14 | 141.6 | – | 3.40–3.50 | 0.70–0.80 | A | |
| I | II 1(F) | 53.69 | 5.57 | 70.8 | 80 | 2.70–3.00 | 0.60–0.70 | A |
| II 2(F) | 53.69 | 5.57 | 70.8 | 80 | 2.60–2.90 | 0.60–0.70 | A | |
| J | II 1(F) | 93.10 | 11.14 | 141.6 | 80 | 3.40–3.90 | 0.80–0.90 | A |
| K | II 1(M) | 13.42 | 1.86 | 23.6 | – | 2.60–2.70 | 0.60–0.80 | A |
| L | II 1(F) | 40.27 | 11.14 | 141.6 | – | 3.00–3.60 | 0.60–0.70 | A |
| M | II 1(F) | 60.40 | 5.57 | 70.8 | – | 3.00–3.10 | 0.70–0.80 | A |
Each potassium aspartate and magnesium aspartate tablet contains magnesium aspartate 0.140 g (equivalent to 11.8 mg magnesium ion) and potassium aspartate 0.158 g (equivalent to 36.2 mg potassium ion)
M male, F female, PAMA potassium aspartate and magnesium aspartate tablets, Sp spironolactone, A asymptomatic
–No supplement, ※Intravenous supplement of KCl 13.42 mmol/4-5 day and MgSO4 2.5 g/4–5 day